Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis

Summary Background In 2013 England and Wales began to fund a live attenuated influenza vaccine programme for individuals aged 2–16 years. Mathematical modelling predicts substantial beneficial herd effects for the entire population as a result of reduced influenza transmission. With a decreased influenza-associated disease burden, existing immunisation programmes might be less cost-effective. The aim of this study was to assess the epidemiological effect and cost-effectiveness of the existing elderly and risk group vaccination programme under the new policy of mass paediatric vaccination in England. Methods For this cost-effectiveness analysis, we used a transmission model of seasonal influenza calibrated to 14 seasons of weekly consultation and virology data in England and Wales. We combined this model with an economic evaluation to calculate the incremental cost-effectiveness ratios, measured in cost per quality-adjusted life-years (QALY) gained. Findings Our results suggest that well timed administration of paediatric vaccination would reduce the number of low-risk elderly influenza cases to a greater extent than would vaccination of the low-risk elderly themselves if the elderly uptake is achieved more slowly. Although high-risk vaccination remains cost-effective, substantial uncertainty exists as to whether low-risk elderly vaccination remains cost-effective, driven by the choice of cost-effectiveness threshold. Under base case assumptions and a cost-effectiveness threshold of £15 000 per QALY, the low-risk elderly seasonal vaccination programme will cease to be cost-effective with a mean incremental cost-effectiveness ratio of £22 000 per QALY and a probability of cost-effectiveness of 20%. However, under a £30 000 per QALY threshold, the programme will remain cost-effective with 83% probability. Interpretation With the likely move to decreased cost-effectiveness thresholds, reassessment of existing risk group-based vaccine programme cost-effectiveness in the presence of the paediatric vaccination programme is needed. Funding National Institute for Health Research, the Medical Research Council.

[1]  Ellen Brooks-Pollock,et al.  Measured Dynamic Social Contact Patterns Explain the Spread of H1N1v Influenza , 2012, PLoS Comput. Biol..

[2]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[3]  J. Mossong,et al.  Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight European countries , 2009, BMC infectious diseases.

[4]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[5]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[6]  T. Heikkinen,et al.  Burden of influenza in children in the community. , 2004, The Journal of infectious diseases.

[7]  S. de Lusignan,et al.  Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  L. Grohskopf,et al.  Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. , 2013, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  S de Lusignan,et al.  Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[10]  R. Booy,et al.  Vaccination and herd immunity: what more do we know? , 2012, Current opinion in infectious diseases.

[11]  A. Palache.  Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. , 2011, Vaccine.

[12]  A. Monto.  Seasonal influenza vaccinations: specialized products for different target groups. , 2010, Vaccine.

[13]  Maik Kschischo,et al.  Potassium Starvation in Yeast: Mechanisms of Homeostasis Revealed by Mathematical Modeling , 2012, PLoS Comput. Biol..

[14]  W. John Edmunds,et al.  Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study , 2015, BMC Medicine.

[15]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[16]  W. John Edmunds,et al.  Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study , 2013, PLoS medicine.

[17]  R. Mikolajczyk,et al.  Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases , 2008, PLoS medicine.

[18]  W. Edmunds,et al.  Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  Joanna Ellis,et al.  Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  E. Vermeire,et al.  A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. , 2011, Vaccine.

[21]  S. de Lusignan,et al.  Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[22]  John J. Grefenstette,et al.  A computer simulation of employee vaccination to mitigate an influenza epidemic. , 2010, American journal of preventive medicine.